Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial

What Was Tested

This randomized controlled trial paper looks at Relamorelin.

To determine short-term effects of relamorelin on colonic motility measured by barostat and multilumen manometry in CC.

Why It Was Studied

The pentapeptide ghrelin agonist, relamorelin, accelerates colonic transit in patients with chronic constipation (CC).

Who Took Part

The study group was 12 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Relamorelin and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Relamorelin, so expectations could not easily colour the readings.

Some patients received a placebo instead of Relamorelin, giving a reference point.

A motility-barostat balloon assembly was used to measure colonic compliance; tone and phasic pressure activity were measured before and after a 1000-kcal milkshake meal (administered ~60 min post-medication).

Overall "background" phasic pressure activity was assessed by: average amplitude and motility index (MI = ln[sum amplitudes × #contractions + 1]) over defined periods.

High-amplitude propagating contractions (HAPCs) were characterized by amplitude >75 mmHg and propagating contractions >50 mmHg; both were propagated over at least 10 cm.

Postprandial HAPCs were the primary end point.

What Was Measured

PubMed files the paper under topics including Chronic Disease, Colon, Descending, Compliance, Constipation, Gastrointestinal Motility, Manometry and Oligopeptides.

The authors tagged it with the keywords Colonic transit and Ghrelin agonist.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Relamorelin in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Digestive diseases and sciences), a journal based in United States.

More context: the Relamorelin compound page, all human trials.